Sesderma expands India push as demand for science-backed skincare gains momentum
Our partnership with Sesderma is built on a shared commitment to scientific excellence, innovation, and delivering advanced derma-tech in India
Our partnership with Sesderma is built on a shared commitment to scientific excellence, innovation, and delivering advanced derma-tech in India
Consolidated EBITDA excluding real estate stood at Rs. 22.3 crore, declining 37% YoY and 10% QoQ
Drug formulations and biologicals remained the largest export category, contributing USD 5.98 billion and accounting for 73.85% of total pharmaceutical exports
Company's profit before tax increased 39% year-on-year to Rs. 435 crore, while profit after tax rose 47% to Rs. 317 crore from Rs. 215.5 crore in Q1 FY26
The three-day event will bring together pharmaceutical manufacturers, biotech companies, regulators, consultants, suppliers and technology innovators
The transaction is expected to close in Q4 2026, subject to applicable Indian regulatory requirements and customary closing conditions
The company invested Rs. 642 crore in R&D during the quarter, representing 8% of revenues, while organic capex stood at Rs. 585 crore
The roughly 600,000-square-foot campus at Generation Park will be designed to grow and adapt for decades
Revenue from operations rose to Rs. 2,229 crore in Q1 FY27 from Rs. 1,901 crore a year earlier
Revenue from operations surged 37.1% year-on-year (YoY) to Rs. 756.3 crore in Q1 FY27
The company reported operating revenue of Rs. 1,167 crore in Q1 FY27
The portfolio includes both oncology and non-oncology products, covering vials, lyophilised formulations, ampoules and pre-filled syringes
The investment will support Biodeal’s expansion across Asian markets while accelerating its growth across the CIS, Latin America, Africa and Europe
Evotec is eligible for milestone payments tied to the successful delivery of validated hit series for each target. The companies did not disclose financial terms
The authorisation is supported by the Phase III REMIX-1 and REMIX-2 trials,
The collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare broaden Philips’ wearable and out-of-hospital monitoring capabilities
Profit before exceptional items and tax stood at Rs. 510 million, while profit after exceptional items and tax was Rs. 507 million during the quarter.
LifeCell and Shraddha Diagnostics plan to expand their diagnostic services across state, providing clinicians and patients with access to a broader range of diagnostic capabilities
Subscribe To Our Newsletter & Stay Updated